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Don’t Forget the Intervention
in Very Elderly Persons With
Acute Coronary Syndromes*
Freek W. A. Verheugt, MD
Amsterdam, the Netherlands
The most common admission indication in the cardiology
practice is acute coronary syndrome (ACS) with or without
ST-segment elevation. Antithrombotic and anti-ischemic
therapies are the cornerstones in the medical management
of these syndromes. In patients presenting with ST-
segment elevation at the admission electrocardiogram, rep-
erfusion therapy is instituted as fast as possible (1–3), which
can be accomplished by primary percutaneous coronary
intervention, fibrinolysis, or both. This results in a signifi-
cant reduction in infarct size and improvement of short- and
long-term prognosis (2,3). In patients with coronary syn-
dromes presenting without ST-segment elevation on the
admission electrocardiogram, anti-ischemic and antithrom-
See page 906
botic therapies are also of utmost importance. However, in
the last decade a strong switch has been seen in the invasive
approach of this condition. Risk stratification can be im-
proved by angiography, and revascularization—if indicated—
can be planned. Several randomized trials have evaluated a
routine invasive strategy in comparison with a more selective
invasive approach in these patients. The outcome results
were mixed (4–6). Although these meta-analyses included
trials from the pre-clopidogrel era, a routine invasive strat-
egy has already shown a reduction in myocardial infarction
and repeat intervention. The results with regard to early and
long-term survival were variable. There seemed to be an
early hazard for early mortality compensated by a later
reduction (4).
The substrate of a non–ST-segment elevation myocardial
infarction usually does not consist of an acutely occluded
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erck, The Medicines Company, and Bayer Healthcare.epicardial coronary artery, like in ST-segment elevation
myocardial infarction. In non-ST-segment elevation ACS
there can be severe but non-occlusive coronary artery disease
or no disease at all. In the large TACTICS–TIMI 18 (Treat
angina with Aggrastat and determine Costs of Therapy with
Invasive or Conservative Strategies–Thrombolysis in Myo-
cardial Infarction 18) study, 43% of patients had left main or
triple-vessel disease, and 13% had normal coronary arteries
(7). In both instances reperfusion therapy is not indicated
and only leads to harm by bleeding and excess myocardial
infarction (8,9). In a meta-analysis of the 3 most recent large
trials in this syndrome, it was shown that in only the
highest-risk patients is there a mortality benefit by an early
routine invasive approach, whereas the lower-risk patients
have no mortality benefit at all (6). Therefore, current
European and American guidelines on non–ST-segment
elevation ACS do not recommend an early invasive strategy
in low-risk patients (10,11). The strength of the latter
meta-analysis is that it was based on individual patient data.
The weakness is that it is constructed from trials, which are
necessarily open by design and in which myocardial infarc-
tion is both an entry criterion and an endpoint at the same
time.
In this issue of JACC: Cardiovascular Interventions, a
highly interesting trial is presented on a routine invasive
strategy versus a selective invasive strategy in non-ST-
segment elevation ACS carried out exclusively in very
elderly patients (over 80 years of age) (12). The appealing
feature of this Italian study is that it is the first and only trial
available performed specifically in very elderly patients with
this syndrome. But the weakness is that the trial did not
reach its aim with regard to the number of recruited
patients. It clearly shows that in very elderly patients a
routine invasive strategy can be helpful without clear excess
harm. In the individual data meta-analysis mentioned in the
preceding text (6), it was already shown that age is the
strongest predicting factor for improved outcome by a
routine invasive strategy, which is now confirmed by the
current prospective study. These findings underscore that a
factor identified in a meta-analysis can only be confirmed in
a prospective randomized study in patients with such a
feature.
Should all very elderly patients admitted with this syn-
drome undergo a routine invasive approach? Clearly, each
case should be considered individually. Furthermore, in this
Italian study only patients with a positive biomarker bene-
fited from the therapy. This is a post hoc finding, the effect
of which should be evaluated in a future prospective
randomized trial, as pointed out in the preceding text. A
good example of such an approach is the outcome of the
large ICTUS (Invasive versus Conservative Treatment in
Unstable coronary Syndromes) trial (13). In the years before
the ICTUS trial, a positive biomarker indicated a higher
risk for this group of patients. To prove this prospectively,
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918the ICTUS trial included only patients with positive tro-
ponin levels. But it turned out that there was no benefit of
a routine invasive approach in these high-risk patients,
although 53% of the patients in the selective-invasive arm
crossed-over to angiography like 51% of those patients in
the TACTICS–TIMI 18 study (7).
So, the results of the current trial in very elderly patients
should be repeated prospectively in similar patients but only
in those with positive biomarkers. If that study should turn
out to be positive, then together with the data presented
today a routine invasive strategy would be strongly indicated
in very elderly patients admitted with non-ST-segment
elevation ACS and positive biomarkers.
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